Inhibikase Therapeutics, Inc. financial data

Symbol
IKT on Nasdaq
Location
Wilmington, DE
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1296% % 458%
Debt-to-equity 8.3% % -89%
Return On Equity -57% % 84%
Return On Assets -53% % 74%
Operating Margin -2006393700% % -32475675%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75,175,306 shares 12%
Common Stock, Shares, Outstanding 74,807,911 shares 902%
Entity Public Float $7,700,000 USD -60%
Common Stock, Value, Issued $74,808 USD 902%
Weighted Average Number of Shares Outstanding, Basic 90,050,973 shares 914%
Weighted Average Number of Shares Outstanding, Diluted 90,050,973 shares 914%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $30,627,809 USD 135%
Costs and Expenses $51,127,354 USD 155%
Operating Income (Loss) $51,127,354 USD -155%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $47,657,115 USD -144%
Earnings Per Share, Basic 0 USD/shares 80%
Earnings Per Share, Diluted 0 USD/shares 80%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $56,500,000 USD 514%
Marketable Securities, Current $39,052,511 USD 1576%
Assets, Current $78,536,628 USD 1774%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $57,913 USD
Assets $79,594,541 USD 1719%
Accounts Payable, Current $620,528 USD -75%
Accrued Liabilities, Current $3,656,383 USD 69%
Liabilities, Current $6,696,243 USD 36%
Operating Lease, Liability, Noncurrent $25,606 USD -83%
Liabilities $6,696,243 USD 36%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,189 USD -339%
Retained Earnings (Accumulated Deficit) $129,945,149 USD -58%
Stockholders' Equity Attributable to Parent $72,898,298 USD
Liabilities and Equity $79,594,541 USD 1719%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,103,530 USD -6.1%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $21,054,342 USD
Common Stock, Shares Authorized 500,000,000 shares 400%
Common Stock, Shares, Issued 74,807,911 shares 902%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38,269,706 USD 4090%
Deferred Tax Assets, Valuation Allowance $23,217,835 USD 24%
Deferred Tax Assets, Gross $23,217,835 USD 24%
Operating Lease, Liability $37,944 USD -79%
Depreciation $67,066 USD 155%
Payments to Acquire Property, Plant, and Equipment $13,399 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $5,775,288 USD -26%
Lessee, Operating Lease, Liability, to be Paid $38,322 USD -80%
Property, Plant and Equipment, Gross $117,224 USD 13%
Operating Lease, Liability, Current $152,224 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $114,966 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $38,322 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $378 USD -97%
Deferred Tax Assets, Operating Loss Carryforwards $12,320,874 USD 34%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $18,684,606 USD 5172%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%